OSE Immuno: share price soars following partnership with AbbVie
At around 11:30 a.m., shares in the Nantes-based immunotherapy company were the biggest risers on the Paris market, gaining more than 58%.
Reserved for the upside at the start of the day, shares had gained as much as 82% by around 9:30 a.m. The agreement covers the development of an innovative monoclonal antibody, OSE-230.
The collaboration and licensing agreement with AbbVie covers the development of an innovative monoclonal antibody, OSE-230, designed to resolve chronic inflammation.
Under the terms of the partnership, OSE Immunotherapeutics will receive a payment of $48 million on signature of the contract, and could receive up to a further $665 million in the form of milestone payments.
In a reaction note, analysts at Degroof Petercam - Buy on the stock with a price target of 7.3 euros - refer to a "historic agreement" from the company's point of view.
According to the Belgian investment house, OSE should allocate these funds to its Phase 3 clinical trial on Tedopi, its most advanced product currently in oncology trials in several solid tumors.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction